In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GPOs Rethink Diagnostics

Executive Summary

As major GPOs come under pressure from a variety of sources they are refining their approach to laboratory purchasing, with ramifications for suppliers. Groups are getting tougher on compliance and contracting with fewer lab vendors but the trade-off is less choice for lab members. The more the purchasing process restricts vendors, the more it benefits a few at the expense of many.

You may also be interested in...



The State of Laboratory Unions

Hospital laboratory consolidation, underway for several years, is having mixed success as the market shifts. For suppliers, things are unlikely to settle down soon. Successful labs claim to be committed to a common vision and to swift action to institute painful changes. But other labs are stymied by politics, lack of top management support, and reluctance to make difficult decisions quickly. Manufacturers' expectations that consolidation would lead to standardization of equipment and a winner-take-all mentality are starting to come to pass. But the customer base continues to be in more flux than expected.

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel